Establishment and characterization of cell lines from chromosomal instable colorectal cancer

Abstract

AIM: To generate novel tumor models for preclinical validation of biomarkers that allow drug response prediction and individual therapeutic decisions.

METHODS: Cell line establishment was conducted by both direct in vitro culturing and in vivo xenografting followed by in vitro culturing procedure. A comprehensive characterization was subsequently performed. This included quality control, consisting of the confirmation of human and colorectal cancer (CRC) origin by DNA fingerprint and epithelial cell adhesion molecule (EpCAM) staining, as well as mycoplasma and human virus testing. Phenotypic analysis was done by light microscopy and multicolor flow cytometry. Histopathological examination (β-catenin and cytokeratin staining) was conducted in direct comparison to parental tumor tissues. Extensive molecular-pathological profiling included mutation analysis for CRC-associated driver mutations, assessment of chromosomal and microsatellite instability, and the grade of CpG island methylation. Additionally, an array-based comparative genomic hybridization analysis was performed. Drug responsiveness was assessed for a panel of classical and novel substances in clinical use for the treatment of solid cancers. Finally, tumorigenicity of the cell lines was tested by xenografting into immunocompromised nude mice.

RESULTS: Herein we describe the establishment of three ultra-low passage cell lines from two individual patients suffering from sporadic CRC. One cell line was derived directly from an early stage case (HROC18), whereas two cell lines could be established both direct from patient material and after xenografting from a late stage tumor (HROC32). All cell lines were free of contaminating mycoplasma and viruses. Molecular-pathological analysis allowed all cell lines to be classified as chromosomal instable (CIN⁺). They were aneuploid, with CpG island promoter methylation and microsatellite instability being absent. The following mutational profile was observed both in the cell lines and the parental tumor tissue: HROC18: APC^mut, p53^mut, K-ras^wt; HROC32: APC^wt, p53^mut, K-ras^mut. All cell lines were characterized as epithelial (EpCAM⁺) cells, showing distinct morphology and migration speed, but comparable growth kinetics. The cell lines showed different patterns of response towards clinically approved and novel drugs, with HROC18 being more resistant than HROC32 cells. Finally, in vivo tumorigenicity was demonstrated.

CONCLUSION: We successfully established and characterized novel ultra-low passage patient-derived CRC models as useful instruments for analyzing biological characteristics associated with the CIN⁺ phenotype.

Keywords: Patient-derived tumor model; Colorectal cancer; Individualized medicine; Molecular characterization; Drug response; Translational research

Core tip: We ultra-low passage and well-characterized tumor models are considered the basis for modern preclinical research, but are still rare for colorectal carcinoma (CRC). Herein describe two novel ultra-low passage patient-derived CRC cell lines, HROC18 and HROC32, which were established both direct from patient material and after xenografting. We characterized these models according to phenotype, molecular, morphological, and growth characteristics, as well as by drug response profiles. These cell lines expand our comprehensive collection of tumor models, which in summary provide a useful instrument for basic and translational research. The models are available on request.